News & Updates

First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.

The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.

In critically ill patients with community-acquired pneumonia (CAP), treatment with corticosteroids has significantly reduced the need for mechanical ventilation, while use of hydrocortisone has prevented many hospital deaths.

Patients with chronic obstructive pulmonary disease (COPD), especially those with concurrent chronic bronchitis and emphysema phenotypes, are prone to the development of cardiovascular disease (CVD), a recent study has shown.